FIELD: biotechnology.
SUBSTANCE: disclosed are: an antibody or antigen-binding fragment specific for a DOTAM-lead (Pb) chelate, containing an antigen-binding site, bispecific antibody specific for chelate DOTAM-lead (Pb) and tumour-specific antigen selected from CEA, HER2 and CD20, and methods for their production. Also disclosed are isolated polynucleotides which encode antibodies, sets of isolated polynucleotides, expression vectors containing polynucleotides, sets of expression vectors, host cells containing an isolated polynucleotide or a set of isolated polynucleotides for producing an antibody or an antigen-binding fragment or a bispecific antibody.
EFFECT: invention can be used in such fields as radioimmunoimaging and radioimmunotherapy.
34 cl, 62 dwg, 84 tbl, 37 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES THAT BIND TO CANCER CELLS AND PROVIDE TARGETED TRANSFER OF RADIONUCLIDES TO SAID CELLS | 2020 |
|
RU2833191C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTI-SIGLEC-9 ANTIBODY MOLECULES | 2020 |
|
RU2833330C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
